Selective Histone Deacetylase Inhibitors with Anticancer Activity

Author(s): Nan Ma, Ying Luo, Ying Wang, Chenzhong Liao, Wen-Cai Ye, Sheng Jiang.

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 4 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

HDAC inhibitors (HDACIs), which can be used to kill cancer cells through inhibiting histone deacetylase activity or altering the structure of chromatin, have emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC inhibitors including class-selective and isoform-selective HDAC inhibitors.

Keywords: Class I, Class II, Class III, HDAC, HDAC1, HDAC6, Selective histone deacetylase inhibitors.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 4
Year: 2016
Page: [415 - 426]
Pages: 12
DOI: 10.2174/1568026615666150813145629
Price: $58

Article Metrics

PDF: 86
HTML: 2
EPUB: 1